BioNxt Solutions Inc.
Research BioNxt Solutions Inc. (BXT) on Bullrun: market cap EUR 27.76M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBXT
- ExchangeXETRA
- CountryCanada
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 27.76M
- Financial periodQ1 2026
- RevenueCAD 0
- Net income-CAD 4.25M
- Free cash flow-CAD 588.29K
Valuation Snapshot
latest market cap is EUR 27.76M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 7.03M | -CAD 5.20M | n/a | n/a | CAD 55.26K | CAD 5.95M | -CAD 9.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-17 | EUR 27.76M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioNxt Solutions Inc.'s market cap?
BioNxt Solutions Inc.'s market capitalization is EUR 27.76M.
What does BioNxt Solutions Inc. do?
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor.